

The Office of Generics Drugs (OGD) has been reorganized to improve coordination, communication, efficiency and to enhance the Office's ability to assure that all generic drugs are safe, effective, high quality and interchangeable to the brand name drug product/reference listed drug. The organization adds another Division to both the Bioequivalence and Chemistry programs, and converts the Microbiology and Clinical Review Staffs into Divisions. It also formalizes the position of Deputy Director for Science and Chemistry. Here is the new structure.

#### OFFICE OF GENERIC DRUGS

Division of Bioequivalence I

Division of Bioequivalence II

Division of Labeling and Program Support

Division of Microbiology

Division of Clinical Review

Division of Chemistry I

Division of Chemistry II

Division of Chemistry III

Division of Chemistry IV

The reorganization is a major step in CDER's efforts to advance the public health as the use of generic drugs continues to increase.